{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T22:07:31Z","timestamp":1770674851937,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tumor human papillomavirus (HPV) status has emerged as one of the most powerful prognostic factors for disease control and survival in patients with oropharyngeal squamous cell carcinoma (OPSCC). We reviewed our experience in patients with OPSCC and known tumor HPV status treated with definitive chemoradiotherapy (CRT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with stage III-IVb OPSCC and known tumor HPV status treated with CRT between 2006 and 2011 were identified from an IRB approved registry for this retrospective review. Outcomes were estimated using the Kaplan-Meier method and compared between HPV-positive and negative patients using the log-rank test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 121 pts (89% male, 93% Caucasian) included in this study, median age was 57 (range: 40\u201373) and median follow-up was 21\u00a0months (range: 6\u201363). Ninety-seven (80%) patients were HPV-positive and 24 (20%) were HPV-negative. Primary site was base of tongue (55%), tonsil (44%), and oropharyngeal wall (2%). Two year rates of locoregional recurrence (3% vs. 26%; p\u2009=\u20090.002), disease free survival (93% vs. 64%; p\u2009=\u20090.001) and overall survival (94% vs 73%; p\u2009=\u20090.002) were superior in HPV-positive patients, while rates of distant recurrence were similar (3% vs. 5%; p\u2009=\u20090.98). While acute toxicities were similar between both groups, patients with HPV-positive disease were more likely to resume a normal diet (90% vs. 65%; p\u2009=\u20090.017) at last follow up. Also, no HPV-positive patient required a feeding tube beyond 6\u00a0months after treatment, compared with 24% of HPV-negative patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Definitive CRT produces excellent rates of disease control with minimal late toxicity for patients with HPV-positive OPSCC. Studies of OPSCC should account for tumor HPV status when identifying factors prognostic for outcome.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1748-717x-8-174","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T08:15:37Z","timestamp":1373357737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Oropharyngeal squamous cell carcinoma with known human papillomavirus status treated with definitive chemoradiotherapy: patterns of failure and toxicity outcomes"],"prefix":"10.1186","volume":"8","author":[{"given":"Trevor J","family":"Bledsoe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anisha R","family":"Noble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant K","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A","family":"Rybicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Hoschar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah J","family":"Chute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerrold P","family":"Saxton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F","family":"Greskovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Adelstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shlomo A","family":"Koyfman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,9]]},"reference":[{"key":"895_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jama.2012.101","volume":"307","author":"ML Gillison","year":"2012","unstructured":"Gillison ML, Broutian T, Pickard RKL, Tong Z-y, Xiao W, Kahle L, Graubard BI, Chaturvedi AK: Prevalence of oral HPV infection in the United States, 2009\u20132010. JAMA 2012, 307: 693-703. 10.1001\/jama.2012.101","journal-title":"JAMA"},{"key":"895_CR2","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","volume":"29","author":"AK Chaturvedi","year":"2011","unstructured":"Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, et al.: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011, 29: 4294-4301. 10.1200\/JCO.2011.36.4596","journal-title":"J Clin Oncol"},{"key":"895_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/jnci\/djn025","volume":"100","author":"ML Gillison","year":"2008","unstructured":"Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R: Distinct risk factor profiles for human papillomavirus type 16\u2013positive and human papillomavirus type 16\u2013negative head and neck cancers. J Natl Cancer Inst 2008, 100: 407-420. 10.1093\/jnci\/djn025","journal-title":"J Natl Cancer Inst"},{"key":"895_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jnci\/djn011","volume":"100","author":"C Fakhry","year":"2008","unstructured":"Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML: Improved survival of patients with human papillomavirus\u2013positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008, 100: 261-269. 10.1093\/jnci\/djn011","journal-title":"J Natl Cancer Inst"},{"key":"895_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, et al.: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363: 24-35. 10.1056\/NEJMoa0912217","journal-title":"N Engl J Med"},{"key":"895_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1158\/1078-0432.CCR-05-2017","volume":"12","author":"RJC Slebos","year":"2006","unstructured":"Slebos RJC, Yi Y, Ely K, Carter J, Evjen A, Zhang X, Shyr Y, Murphy BM, Cmelak AJ, Burkey BB, et al.: Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006, 12: 701-709. 10.1158\/1078-0432.CCR-05-2017","journal-title":"Clin Cancer Res"},{"key":"895_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/jnci\/92.9.709","volume":"92","author":"ML Gillison","year":"2000","unstructured":"Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, et al.: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000, 92: 709-720. 10.1093\/jnci\/92.9.709","journal-title":"J Natl Cancer Inst"},{"key":"895_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1067\/mhn.2001.116979","volume":"125","author":"SR Schwartz","year":"2001","unstructured":"Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM: Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 2001, 125: 1-9. 10.1067\/mhn.2001.116979","journal-title":"Otolaryngol Head Neck Surg"},{"key":"895_CR9","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/ijc.22851","volume":"121","author":"CCR Ragin","year":"2007","unstructured":"Ragin CCR, Taioli E: Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007, 121: 1813-1820. 10.1002\/ijc.22851","journal-title":"Int J Cancer"},{"key":"895_CR10","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1200\/JCO.2010.29.2904","volume":"28","author":"D Rischin","year":"2010","unstructured":"Rischin D, Young RJ, Fisher R, Fox SB, Le Q-T, Peters LJ, Solomon B, Choi J, O'Sullivan B, Kenny LM, McArthur GA: Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010, 28: 4142-4148. 10.1200\/JCO.2010.29.2904","journal-title":"J Clin Oncol"},{"key":"895_CR11","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1200\/JCO.2005.04.6136","volume":"24","author":"L Licitra","year":"2006","unstructured":"Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cant\u00f9 G, Squadrelli M, et al.: High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006, 24: 5630-5636. 10.1200\/JCO.2005.04.6136","journal-title":"J Clin Oncol"},{"key":"895_CR12","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1200\/JCO.2005.01.5867","volume":"24","author":"DJ Adelstein","year":"2006","unstructured":"Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M, Lavertu P, Lorenz RR, Carroll MA: Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 2006, 24: 1064-1071. 10.1200\/JCO.2005.01.5867","journal-title":"J Clin Oncol"},{"key":"895_CR13","volume-title":"Common terminology criteria for adverse events (CTCAE) Rev. edn","author":"National Cancer Institute (U.S.)","year":"2009","unstructured":"National Cancer Institute (U.S.): Common terminology criteria for adverse events (CTCAE) Rev. edn. Bethesda, MD: U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute; 2009."},{"key":"895_CR14","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.ijrobp.2011.03.029","volume":"82","author":"BH Lok","year":"2012","unstructured":"Lok BH, Setton J, Caria N, Romanyshyn J, Wolden SL, Zelefsky MJ, Park J, Rowan N, Sherman EJ, Fury MG, et al.: Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes. Int J Radiat Oncol Biol Phys 2012, 82: 1851-1857. 10.1016\/j.ijrobp.2011.03.029","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"895_CR15","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ijrobp.2007.05.017","volume":"69","author":"CW Hodge","year":"2007","unstructured":"Hodge CW, Bentzen SM, Wong G, Palazzi-Churas KL, Wiederholt PA, Gondi V, Richards GM, Hartig GK, Harari PM: Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? an inter-era comparison. Int J Radiat Oncol Biol Phys 2007, 69: 1032-1041. 10.1016\/j.ijrobp.2007.05.017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"895_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.ijrobp.2008.10.060","volume":"74","author":"TH La","year":"2009","unstructured":"La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, Maxim P, Quon A, Graves EE, Loo BW Jr, Le Q-T: Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009, 74: 1335-1341. 10.1016\/j.ijrobp.2008.10.060","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"895_CR17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ijrobp.2010.10.061","volume":"82","author":"S Clavel","year":"2012","unstructured":"Clavel S, Nguyen DHA, Fortin B, Despr\u00e9s P, Khaouam N, Donath D, Souli\u00e8res D, Guertin L, Nguyen-Tan PF: Simultaneous integrated boost using intensity-modulated radiotherapy compared with conventional radiotherapy in patients treated with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2012, 82: 582-589. 10.1016\/j.ijrobp.2010.10.061","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"895_CR18","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.ijrobp.2011.06.034","volume":"81","author":"J Setton","year":"2011","unstructured":"Setton J, Rao SD, Lian M, Lok B, Sherman E, Ganly I, Wong R, Lee NY: Low-lying cervical metastases predict for distant metastasis in N2 oropharyngeal cancer patients treated with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 2011, 81: S17.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"895_CR19","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1200\/JCO.2007.14.8841","volume":"26","author":"M Machtay","year":"2008","unstructured":"Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK: Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008, 26: 3582-3589. 10.1200\/JCO.2007.14.8841","journal-title":"J Clin Oncol"},{"key":"895_CR20","first-page":"14","volume":"2012","author":"SA Dowthwaite","year":"2012","unstructured":"Dowthwaite SA, Franklin JH, Palma DA, Fung K, Yoo J, Nichols AC: The role of transoral robotic surgery in the management of oropharyngeal cancer: a review of the literature. ISRN Oncol 2012, 2012: 14.","journal-title":"ISRN Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1748-717X-8-174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:43:13Z","timestamp":1630543393000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/1748-717X-8-174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,9]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["895"],"URL":"https:\/\/doi.org\/10.1186\/1748-717x-8-174","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,9]]},"assertion":[{"value":"1 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"174"}}